Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada Journal Article


Authors: Hanley, G. E.; Kaur, P.; Berchuck, A.; Chase, A.; Grout, B.; McKinnon Deurloo, C.; Pike, M.; Richardson, J.; Terry, K. L.; Webb, P. M.; Pearce, C. L.
Article Title: Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada
Abstract: Objectives: Research examining survival among people with ovarian cancer following use of statins or β-blockers has been conflicting. Many studies to date have suffered from immortal time bias and/or had limited power. To address these limitations, we used time-dependent analyses to study the association between statin or β-blocker use among all people diagnosed with an epithelial ovarian cancer in British Columbia, Canada between 1997 and 2015. Methods: Population-based administrative data were linked for 4207 people with ovarian cancer. Statin or β-blocker use was examined using time-dependent variables for any use, cumulative duration of use and by user-group according to whether use was initiated before or after their ovarian cancer diagnosis. Cox proportional hazards models were run to estimate the association between statin or β-blocker use and survival. Results: Any postdiagnosis use of statins was associated with better ovarian cancer survival in the full cohort (adjusted hazard ratio (aHR) = 0.76, 95% CI 0.64, 0.89) and among women with serous cancers (aHR = 0.80, 95%CI 0.67–0.96). This was primarily driven by new use post-diagnosis (aHR = 0.67, 95%CI, 0.51-0.89), but there was a trend towards better survival among those who continued use from before diagnosis (aHR 0.83, 95%CI, 0.68-1.00). There was no statistically significant association between β-blocker use and survival. Conclusion: Postdiagnosis statin use was associated with improved survival among people with ovarian cancer. Given the consistency of this finding in the literature, we recommend a randomized clinical trial of statin use in people with ovarian cancer. © 2021 Elsevier Inc.
Keywords: survival; ovarian cancer; statins; beta-blockers
Journal Title: Gynecologic Oncology
Volume: 162
Issue: 2
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2021-08-01
Start Page: 461
End Page: 468
Language: English
DOI: 10.1016/j.ygyno.2021.05.021
PUBMED: 34090707
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 September 2021 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Malcolm Pike
    167 Pike